A call for biotech innovations

A leading international research-based pharmaceutical company is calling for Australian scientists to help solve a scientific research dilemma, at the annual AusBiotech conference in Brisbane, October 21–25.

Merck & Co's recently acquired Sirna Therapeutics is at the forefront of global efforts to create novel therapeutics based on RNA interference (RNAi) technology.

The research uses small RNA interference (siRNA) molecules, which silence genes in a sequence-specific manner, as a novel method of combating a variety of diseases. One of the challenges facing the broad applicability of this technology is the transport of these siRNA molecules to the targeted areas of the body where they can be effective.

Australian scientists who believe they may have the necessary technology to deliver siRNA molecules within the body are invited to present their research to top US decision-makers from Merck and Sirna at a special symposium being hosted at the biotechnology industry's annual conference, AusBiotech.

Dr Phil Kearney, of Merck & Co, said "this is a wonderful opportunity for Australian scientists to showcase their work and potentially be part of a major medical break-through in a completely new drug paradigm that could ultimately benefit millions of patients around the world".

The symposium, initiated by Merck & Co and jointly run with AusBio, aims to identify and evaluate delivery technology opportunities for use with RNAi compounds.

A reward of $10,000 is offered to the best presentation.

Researchers can submit abstracts to AusBiotech (www.ausbiotech.org) where they can also register to attend the symposium.